# Measles M (6011): sc-58167



The Power to Question

#### **BACKGROUND**

Measles virus (MV), also known as rubeola, is an acute viral illness that can be complicated by severe pneumonia, diarrhea and encephalitis. A paramyxovirus of the genus Morbillivirus, Measles virus is an enveloped and nonsegmented negative-stranded RNA virus. Because it is spread through respiration, Measles virus is highly contagious and airborne precautions should be taken for all suspected cases. The incubation period of the virus, during which there are no symptoms, normally lasts for 4-12 days. Infected people continue to be contagious from the initial symptoms until 3-5 days after a maculopapular rash appears. After transmission, the virus infects the epithelial cells of its new host, and may also replicate in the urinary tract, conjunctivae, blood vessels, lymphatic system and central nervous system. Humans and various monkey species remain the only known hosts of measles. Measles virus contains two envelope glycoproteins, the haemagglutinin (H) and fusion proteins, which are responsible for membrane fusion and attachment. Measles virus contains a protein that represses genome replication, protein V, which may function as an RNA-binding modulatory factor. The measles viroid consists of several major structural proteins, including fusion (F), nucleocapsid (N), matrix (M) and hemaglutinin (H).

## REFERENCES

- Sheshberadaran, H., Chen, S.N. and Norrby, E. 1983. Monoclonal antibodies against five structural components of measles virus. I. Characterization of antigenic determinants on nine strains of measles virus. Virology 128: 341-353.
- Sato, T.A., Fukuda, A. and Sugiura, A. 1985. Characterization of major structural proteins of measles virus with monoclonal antibodies. J. Gen. Virol. 66: 1397-1409.
- Rima, B.K., Earle, J.A., Yeo, R.P., Herlihy, L., Baczko, K., ter Meulen, V., Carabaña, J., Caballero, M., Celma, M.L. and Fernandez-Muñoz, R. 1995. Temporal and geographical distribution of measles virus genotypes. J. Gen. Virol. 76: 1173-1180.
- 4. Halsey, N.A. 2006. Measles in developing countries. BMJ 333: 1234.
- Centers for Disease Control and Prevention (CDC). 2006. Measles— United States. MMWR Morb. Mortal. Wkly. Rep. 55: 1348-1351.
- Runkler, N., Pohl, C., Schneider-Schaulies, S., Klenk, H.D. and Maisner, A. 2007. Measles virus nucleocapsid transport to the plasma membrane requires stable expression and surface accumulation of the viral matrix protein. Cell. Microbiol. 9: 1203-1214.
- Vijayaraghavan, M., Martin, R.M., Sangrujee, N., Kimani, G.N., Oyombe, S., Kalu, A., Runyago, A., Wanjau, G., Cairns, L. and Muchiri, S.N. 2007. Measles supplemental immunization activities improve measles vaccine coverage and equity: evidence from Kenya, 2002. Health Policy 83: 27-36.
- 8. Tahara, M., Takeda, M. and Yanagi, Y. 2007. Altered interaction of the matrix protein with the cytoplasmic tail of hemagglutinin modulates measles virus growth by affecting virus assembly and cell-cell fusion. J. Virol. 81: 6827-6836.
- 9. Moss, W.J. 2007. Measles still has a devastating impact in unvaccinated populations. PLoS Med. 4: 24.

## **SOURCE**

Measles M (6011) is a mouse monoclonal antibody raised against Rubeolla virus

## **PRODUCT**

Each vial contains 100  $\mu g$   $lgG_1$  in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

#### **APPLICATIONS**

Measles M (6011) is recommended for detection of measles matrix protein of Measles virus (Rubeola) origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Molecular Weight of Measles M: 37 kDa.

## **RECOMMENDED SECONDARY REAGENTS**

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Immunofluorescence: use goat anti-mouse IgG-FITC: sc-2010 (dilution range: 1:100-1:400) or goat anti-mouse IgG-TR: sc-2781 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

## **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### **PROTOCOLS**

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com